- Report
- May 2024
- 135 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- June 2024
- 200 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- October 2024
- 90 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- January 2024
- 25 Pages
United States
From €2685EUR$2,950USD£2,302GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- January 2022
- 60 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Report
- October 2021
- 111 Pages
Latin America, Europe, ... Latin America, Europe, North America
From €4095EUR$4,500USD£3,511GBP
- Report
- October 2024
- 94 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- July 2022
- 78 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Drug Pipelines
- October 2020
- 90 Pages
Global
From €1820EUR$2,000USD£1,560GBP
Chagas Disease is a parasitic infection caused by the protozoan Trypanosoma cruzi. It is endemic in Latin America and affects millions of people in the region. Infectious Diseases Drugs used to treat Chagas Disease include benznidazole and nifurtimox. These drugs are used to treat both acute and chronic forms of the disease. Treatment is often long-term and requires multiple doses.
The Chagas Drug market is largely concentrated in Latin America, where the disease is most prevalent. The market is expected to grow in the coming years due to increased awareness of the disease and the need for more effective treatments. The market is also expected to benefit from the development of new drugs and treatments.
Companies in the Chagas Drug market include GlaxoSmithKline, Merck, Sanofi, and Novartis. These companies are involved in the development and manufacture of drugs used to treat Chagas Disease. Show Less Read more